A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
出版年份 2014 全文链接
标题
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
作者
关键词
-
出版物
BLOOD
Volume 124, Issue 6, Pages 899-906
出版商
American Society of Hematology
发表日期
2014-06-25
DOI
10.1182/blood-2014-02-556308
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
- (2013) A J Jakubowiak et al. LEUKEMIA
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
- (2012) S. H. Armenian et al. BLOOD
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
- (2012) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
- (2011) J. Yang et al. DRUG METABOLISM AND DISPOSITION
- Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
- (2011) Erika Suzuki et al. PLoS One
- Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation
- (2010) Saro H. Armenian et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Cardiovascular Complications of Cancer Therapy
- (2009) Edward T.H. Yeh et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
- (2008) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now